Category
September 26, 2023
Posted on September 26, 2023 at 10:40 am.Shared by Eileen Teves Contacts: Monica Taylor, 210-450-8970, taylorm1@uthscsa.edu, Eileen Teves, 210-450-7239, tevese@uthscsa.edu SAN ANTONIO – Children with cancer were joined by their families as they dipped their hands in finger paint and left their mark on a new Hyundai SUV at The University of Texas Health Science [...]September 19, 2023
Dr Peter J Houghton from Greehey Children’s Cancer Research Institute discusses the obstacles in developing new treatments for childhood cancers and new approaches in preclinical testing. In my previous article for Open Access Government, I focused on the challenges of developing novel therapies for children with glioma, the most prevalent brain cancer in children. Here, [...]September 8, 2023
September is Childhood Cancer Awareness Month, a time to raise awareness of this devastating disease and to support the children and families who are affected by it. Childhood cancer is the leading cause of death by disease for children under the age of 14. Each year, about 15,000 children in the United States are diagnosed [...]August 2, 2023
Click on image below for full agenda _________________________________________________________ Since 2004, UT Health San Antonio, Greehey Children’s Cancer Research Institute’s (Greehey CCRI) mission has been to advance scientific knowledge relevant to childhood cancer, contribute to understanding its causes, and accelerate the translation of knowledge into novel therapies. Greehey CCRI strives to have a national and global impact on [...]June 5, 2023
Project Title: Targeting the RNA modifying enzyme ALKBH5 in Medulloblastoma Principal Investigator: Panneerdoss Subbarayalu Co-Investigators: Manjeet Rao, PhD, Andrew Brenner, MD, PhD., Peter Houghton, PhD. Funding Agency: National Institutes of Health, NATIONAL CANCER INSTITUTE Medulloblastoma is the most common malignant brain cancer in children. Despite the progress in treating medulloblastoma, the 5-year survival rate for high-risk [...]May 8, 2023
Ambassadors from left to right: Gina Baxter (SHP), Avani Ved (SON), Paulomi Modi (GSBS), Alejandra Garcia (LSOM) and Tyler Childs (SOD) Paulomi Modi is a second-year PhD student in the Integrated Biomedical Sciences program at the Graduate School of Biomedical Sciences. At 17, Modi moved to the United States on her own and later graduated [...]January 18, 2023
Jan 17, 2023 | staff reporter NEW YORK – Lantern Pharma on Tuesday said it received feedback from the US Food and Drug Administration that it will use to submit an investigational new drug application for LP-184. The company further plans to begin studying the drug in a Phase I trial of [...]December 15, 2022
Luiz O.F. Penalva, PhD to receive an award from the Mike Hogg Fund in support of his study, “Preventing Senescence Scape to Overcome Tumor Recurrence in Glioblastoma.” Learn more about Dr. Penalva's researchSeptember 20, 2022
Webinar to be hosted on Thursday, Sept. 22, 2022, at 12:00 p.m. ET, register here. Dr. Houghton will discuss challenges in drug development for pediatric cancers and preliminary results from Lantern’s drug candidates in preclinical pediatric cancer models with unmet clinical needs. September 19, 2022 08:50 AM Eastern Daylight Time DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: [...]September 19, 2022
Talk Title: Structured RNAs restrict the N6-adenine methylation (m6dA) activity of human METTL3-METTL14